|
Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors
|
22 September 2017 |
|
1α,25-Dihydroxyvitamin D3 Inhibits Esophageal Squamous Cell Carcinoma Progression by Reducing IL6 Signaling
|
21 September 2017 |
|
Expressions of Somatostatin Receptor Subtypes (SSTR-1, 2, 3, 4 and 5) in Neuroblastic Tumors; Special Reference to Clinicopathological Correlations with International Neuroblastoma Pathology Classification and Outcomes
|
21 September 2017 |
|
Octreotide enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro
|
20 September 2017 |
|
Melatonin Synergizes the Chemotherapeutic Effect of Cisplatin in Ovarian Cancer Cells Independently of MT1 Melatonin Receptors
|
15 September 2017 |
|
Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer
|
15 September 2017 |
|
Pretreatment with melatonin protects against cyclophosphamide-induced oxidative stress and renal damage in mice
|
15 September 2017 |
|
New signalling pathway involved in the anti-proliferative action of vitamin D₃ and its analogues in human neuroblastoma cells. A role for ceramide kinase
|
13 September 2017 |
|
Melatonin: does it have utility in the treatment of hematologic neoplasms?
|
08 September 2017 |
|
Homing peptides as targeted delivery vehicles
|
08 September 2017 |